[Brulamycin in the treatment of urinary infections--microbiological and clinical research].
The authors report the results frop microbiological and clinical studies of the new aminoglucoside antibiotic brulamycin. The susceptibility of 12 392 bacterial strains was determined versus brulamycin and the other routinely applied antibacterial preparations in our country and established that, according to that index brulamycin, in vitro, gives way only to amikin. Fifty two patients with severe uroinfections were treated (30 adults and 22 children) and healing (sterilization of urine) was attained in 10 per cent of the adults and 40,9 per cent of the children. Improvement (reduction of the bacterial number to insignificant value) was established in 42,3 per cent of all patients. In parallel with the favourable microbiological indices, improvement or normalization of the clinical and paracminical indices of the uroinfection were also established. The antibiotic is very well tolerated, by children one-year of age, including. With those properties brulamycin should widely be administered in the clinical practice of uroinfection treatment.
D000293:Adolescent; D000328:Adult; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D014031:Tobramycin / Q000627:therapeutic use*; D014551:Urinary Tract / Q000002:abnormalities / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D014031:Tobramycin
Brulamitsin za lechenie na uroinfektsiite--mikrobiologichni i klinichni prouchvaniia.